Filter
511
Text search:
latent
tuberculosis
Featured
63
130
Language
Document type
360
54
48
22
10
8
5
2
1
Countries
42
20
19
14
11
9
8
8
8
8
7
6
6
6
5
5
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
135
66
17
10
6
4
4
Toolboxes
307
23
18
11
10
8
6
6
5
5
4
4
4
4
4
2
2
1
1
Rezumat. Definiţie. Epidemiologie. Etiologie. Ciclul de transmitere al tuberculozei. Patogenie si imunitate. Leziuni morfologice în tuberculoză.Modul PNEUMOLOGIE
1 mai 2013 – 30 aprilie 2014]Creditat prin decizia CMR nr. 6653/21.12.2012
Accessed at March 2014
Key populations brief.
Chapter 8, Prison and Health, published
Key population brief.
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
The END TB Strategy
Accessed December 2017
Accessed December 2017
Ghidul Pacientului
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implement
...
Rapport sur les populations clés.
Informe sobre poplaciones clave.
Key populations brief.
